Avecho Biotechnology Limited · ASX:AVE
Avecho Biotechnology — Shareholder Meeting (May 2025)
17 slides from Avecho Biotechnology's shareholder meeting presentation, May 27, 2025
Slide 1: Chair's Address & CEO Presentation
ASX Announcement 27 May 2025 Chair’s Address & CEO Presentation Melbourne, Australia, 27 May 2025: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) attaches the Chair’s Address and the Chief Executive Officer’s presentation for the Annual General Meeting of 27 May 2025 to be held
Slide 2: Chair's Address
Chair’s Address Dear Shareholders, I am delighted to share an update on behalf of Avecho Biotechnology Limited for our Annual General Meeting (“AGM”) today. Earlier this year, global pharmaceutical company Sandoz AG (“Sandoz”) made a significant upfront investment in Avecho’s proprietary TPM®-enhanc
Slide 3: Chair's Address: Phase III Clinical Program and Conclusion
Australia is just the start and the commercial validation of a deal with Sandoz has already piqued the interest of additional pharmaceutical companies for the territories available overseas. > Phase III Clinical Program: CBD Soft-Gel Capsule Avecho is currently navigating the final stages of clinica
Slide 4: CEO Presentation
For personal use only CEO Presentation 27th May 2025 www.avecho.com.au | ASX:AVE
Slide 5: Safe Harbour Statement
This presentation, and any differences may be material representations made before, during (whether positive or negative). or after the presentation, may The risks that may cause Avecho‘s Safe Harbour include forward-looking statements actual results, performance or For personal use only that are in
Slide 6: Summary
Summary For personal use only Phase 3 Opportunity Drug Product Commercial Validation › TPM-enhanced cannabidiol (CBD) capsule for insomnia › Commercial licensing deal with Sandoz for Australia › In a pivotal Phase III clinical trial › Attractive terms: substantial revenue upon commercialization Inso
Slide 7: Sandoz overview
Swiss-based multinational Focus on driving access to make a real For personal use only pharmaceutical company spun difference for patients worldwide1 out of Novartis (Market Cap ~$US 22Bn) Purpose Vision Global presence with Pioneering access To be the world’s leading and most valued a portfolio of
Slide 8: Sandoz Australian presence
Australia‘s 2nd largest generics and biosimilars company with a dedicated team focussed on driving OTC medicines For personal use only Nationwide presence and strong partnerships with major pharmacy banner groups Robust distribution network already in place, with the capability to supply every pharm
Slide 9: Partnership Key Terms
Partnership For personal use only Key Terms Sandoz acquires exclusive rights to Avecho’s pharmaceutical Avecho responsible for the completion of the Phase cannabidiol capsule for insomnia in Australia. III trial and supporting development activities Avecho to receive upfront, milestone and royalty p
Slide 10: Forecast market size
Forecast market size For personal use only Insomnia is broadly defined as difficulty initiating or maintaining sleep It affects 10-30% of the population, with 10- 15% of the population classified as chronic1,2 Globally Up to 237M people are affected4 9.5M 3.6M people in Australia people in Australia
Slide 11: Commercial Growth Phase
Europe 20x For personal use only Canada 1.5x Commercial USA 30x China 10x Growth Phase MENA 2x Japan 5x › Commercial validation from multinational pharmaceutical company LATAM 4x › New phase of commercial growth following many Partnered years of hard work advancing the CBD capsule › Australia the fi
Slide 12: Phase III Trial
Phase III Trial For personal use only Enrolment Targets Path Forward 519 patients in total; 210 to interim analysis 1st patient dosed First patient dosed April 2024 Progress 8-week treatment period 70 patients on study medication by end Dec 2024; need further ~150 Treatment A – Placebo before bed Tr
Slide 13: Faster recruitment in 2025
Next Major Faster recruitment in 2025 For personal use only • 70 patients on study medication by end Dec 2024; need further ~150 Milestone: Interim Analysis • Inclusion/Exclusion criteria revised - Previously ineligible patients now eligible • Three new sites added: existing database (>400) of insom
Slide 14: Increasing shareholder value: Dimerix Case Study
Increasing shareholder value Dimerix Case Study For personal use only 5 Dimerix (ASX:DXB) are in a Phase III clinical trial for Focal Segmental Glomeruloscelosis (FSGS) Orphan indication (<200,000 patients in the US) 1. Phase III trial underway: ~$26M market cap 4 3 2. First licensing deal (ANZ, EU,
Slide 15: Company Snapshot
Company Snapshot AVE Corporate Summary AVE ASX Chart – Last 6 months For personal use only Total shares 3.17 Bn Total options1 2.15 Bn A$6.6 M Cash (end Q1 2025) MCAP2 A$12.69 M 1 Various exercise price and expiry dates – AVEOA (2.15B; price 1.2c) expire 10th May 2026 2 As of COB 23rd May 2025
Slide 16: The year in front of us
The year in front of us For personal use only Complete Partner Partner TGA Trial Complete Sign commercial Complete Phase III Partner discussions Commence partner for CBD trial to interim analysis for CBD product in build of TGA insomnia product in › Discuss results with TGA. further territories subm
Slide 17: Questions Welcome
Questions Welcome For personal use only Dr Paul Gavin Melbourne Office Chief Executive Officer Unit A8, 2A Westall Road T. +61 3 9002 5000 Hallmarc Business Park E. pgavin@avecho.com.au Clayton VIC 3168 Australia T: +61 3 9002 5000 E: info@avecho.com.au
Avecho Biotechnology — Shareholder Meeting (May 2025) on 6ix